Cost-effectiveness thresholds play a vital role in healthcare decision-making, helping to ensure that NHS resources are used ...

New analysis presented by the company, together with an improved discount to the price of vamorolone, mean that NICE can now ...

Elranatamab is recommended with managed access as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...

NICE is unable to make a recommendation about the use in the NHS of toripalimab (Loqtorzi) with chemotherapy for untreated advanced oesophageal squamous cell cancer in adults. This is because Shanghai ...

Tools to help you put the guidance into practice.

Elranatamab (Elrexfio, Pfizer) is indicated 'as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, ...

When NICE recommends a treatment as an option for use with managed access, NHS England will make it available according to the conditions in the managed access agreement. This means that, if a patient ...